Novartis' meningitis vaccine meets endpoints

Novartis AG (NYSE:NVS; SIX:NOVN) said its Meningitis B vaccine (4CMenB) met the co-primary endpoints of producing a consistent immune response across three lots of the vaccine, and producing a "robust...